Biogen/Samsung Takeover - Deal Or No Deal?
Biosimilaires : Samsung Bioepis conclut un nouvel accord de commercialisation avec Biogen | MyPharma Editions
Samsung Biologics Buys Bioepis Stake for $2.3 Billion From Biogen - Bloomberg
Samsung Bioepis : ventes record en Europe au T1 | AGENCE DE PRESSE YONHAP
Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache | Fierce Pharma
Biogen Poised for Pipeline Growth, Samsung Eyes New Drug Expansion after $2.3B Joint Venture Deal
Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture - PMLiVE
Samsung Group reportedly in talks to acquire Biogen < Pharma < Article - KBR
Samsung s'associe à Biogen Idec
Biogen to sell equity stake in Samsung Bioepis joint venture for up to $2.3B - Drug Discovery and Development
Samsung in Talks to Buy Alzheimer's Drug Maker Biogen for $42 Billion: Report | Technology News
Samsung Bioepis considering takeover of Biogen's unit: reports
Logo De Société De Biotechnologie De Biogen Image éditorial - Image du médecines, hématologique: 102563960
Samsung Bioepis seeks to buy Biogen biosimilar unit - KED Global
Biogen shares jump higher on report of potential Samsung acquisition
Samsung Bioepis ponders acquiring unit from U.S. partner Biogen
Samsung intéressé par le rachat du laboratoire Biogen | La Presse
Samsung BioLogics says report on Biogen deal talks untrue | Fox Business
Biogen to sell stake in Samsung Bioepis JV for up to $2.3bn
Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million | BioSpace
Biogen Recoups Much-Needed $2.3B with Sale of Samsung Bioepis Stake | BioSpace
Samsung Biologics buys out Biogen in biosim venture for US$2.3B | HealthCare Middle East & Africa Magazine
